Premium
Molecular Detection of Helicobacter pylori and its Antimicrobial Resistance in Brazzaville, Congo
Author(s) -
Ontsira Ngoyi Esther Nina,
Atipo Ibara Blaise Irénée,
Moyen Rachelle,
Ahoui Apendi Philestine Clausina,
Ibara Jean Rosaire,
Obengui O.,
Ossibi Ibara Roland Bienvenu,
Nguimbi Etienne,
Niama Rock Fabien,
Ouamba Jean Maurille,
Yala Fidèle,
Abena Ange Antoine,
Vadivelu Jamuna,
Goh Khean Lee,
Menard Armelle,
Benejat Lucie,
Sifre Elodie,
Lehours Philippe,
Megraud Francis
Publication year - 2015
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/hel.12204
Subject(s) - clarithromycin , tetracycline , helicobacter pylori , levofloxacin , antibiotic resistance , quinolone , microbiology and biotechnology , drug resistance , helicobacter , antibiotics , biology , medicine , virology
Back ground Helicobacter pylori infection is involved in several gastroduodenal diseases which can be cured by antimicrobial treatment. The aim of this study was to determine the prevalence of H. pylori infection and its bacterial resistance to clarithromycin, fluoroquinolones, and tetracycline in Brazzaville, Congo, by using molecular methods. Material and Methods A cross‐ sectional study was carried out between September 2013 and April 2014. Biopsy specimens were obtained from patients scheduled for an upper gastrointestinal endoscopy and were sent to the French National Reference Center for Campylobacters and Helicobacters where they were tested by molecular methods for detection of H. pylori and clarithromycin resistance by real‐time PCR using a fluorescence resonance energy transfer‐melting curve analysis ( FRET ‐ MCA ) protocol, for detection of tetracycline resistance by real‐time PCR on 16S rRNA genes ( rrn A and rrn B), for detection of point mutations in the quinolone resistance‐determining regions ( QRDR ) of H. pylori gyr A gene, associated with resistance to quinolones, by PCR and sequencing. Results This study showed a high H. pylori prevalence (89%), low rates of clarithromycin and tetracycline resistance (1.7% and 2.5%, respectively), and a high rate of quinolone resistance (50%). Conclusion Therefore, the use of standard clarithromycin‐based triple therapy is still possible as an empiric first‐line treatment as well as prescription of bismuth‐based quadruple therapy, which includes tetracycline, but not a levofloxacin‐based triple therapy because of the high rate of resistance to fluoroquinolones.